Gazyva/Gazyvaro (obinutuzumab) was found to significantly improve complete renal response in lupus nephritis patients, ...

In an interview with Applied Clinical Trials Associate Editor Don Tracy, Richard Young, CEO, Cluepoints, offers his key ...

In an interview with Applied Clinical Trials Associate Editor Don Tracy Peter Ronco, CEO, Emmes, discusses the number of ...

In an interview with ACT senior editor Andy Studna at SCOPE Summit, Tenaerts, chief scientific officer, Medable, highlights ...

The art of saying no in clinical trials goes beyond simply delivering news; it involves maintaining relationships and ...

In the ALEXANDRA/IMpassion030 trial, Tecentriq (atezolizumab) added to postoperative chemotherapy was not found to improve ...

In an interview with ACT Associate Editor Don Tracy, Peter Ronco, CEO, Emmes, discusses the "Choosing the Right Allies: ...

Conference breakout session examines the role of strategic partnerships in driving progress for sexual and gender minority ...

In an interview with ACT senior editor Andy Studna at SCOPE Summit, Patil, vice president, digital innovation, IQVIA, ...

Continuing on Day 2 of this year’s SCOPE Summit in Orlando, a noteworthy session examined ways to better recognize and ...

Tips and best practices for empowering professionals to become change agents in their institutions, including clinical trials ...

In an interview with ACT senior editor Andy Studna at SCOPE Summit, Davidson, vice president, product lead - sponsor tech ...